Table 2.

U.S. Food and Drug Administration Approved Immune Checkpoint Inhibitors as of April 2022: Adjuvant and Neoadjuvant Therapies

Organ	Cancer	Immune Checkpoint Inhibitor	Scenario	Cancer Stage	Schedule
Skin	Melanoma	Ipilimumab149	Adjuvant	III	Every 3 wk
		Pembrolizumab150	Adjuvant	II-III	Every 3 or 6 wk
		Nivolumab151	Adjuvant	III	Every 2 or 4 wk
Lung	Non-small cell lung cancer	Nivolumab152	Neoadjuvant	I-III	Every 3 wk
		Atezolizumab153	Adjuvant	II-III	Every 2-4 wk
		Durvalumab154	Adjuvant	III	Every 2 or 4 wk
Urological	Renal cell cancer	Pembrolizumab155	Adjuvant	II-IV	Every 3 or 6 wk
	Urothelial carcinoma	Nivolumab156	Adjuvant	III	Every 2 or 4 wk
Gastrointestinal	Gastric and gastroesophageal cancer	Nivolumab157	Adjuvant	II-III	Every 2 or 4 wk
Breast	Triple negative breast cancer	Pembrolizumab38	Adjuvant and neoadjuvant	II-III	Every 3 or 6 wk

Abbreviations as in Table 1.